|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Different strategies of treatment for uterine cervical carcinoma stage ⅠB2-ⅡB显示文摘Uterine cervical cancer is the second most common gynecological malignancy. It is estimated that over 35% of tumors are diagnosed at locally advanced disease, stage ⅠB2-ⅡB with an estimated 5-year overall survival of 60%. During the last decades, the initial treatment for these women has been debated and largely varies through different countries. Thus, radical concurrent chemoradiation is the standard of care in United Sated and Canada, and neoadjuvant chemotherapy followed by radical surgery is the first line of treatment in some institutions of Europe, Asia and Latin America. Until today, there is no evidence of which strategy is better over the other. This article describe the evidence as well as the advantages and disadvantages of the main strategies of treatment for women affected by uterine cervical cancer stage ⅠB2-ⅡB. | Lucas Minig María Guadalupe Patrono Nuria Romero Juan Francisco Rodríguez Moreno Jesús Garcia-Donas | 2014 | World Journal of Clinical Oncology2014，5，2： | 46 |
| 2 | Hepatitis C virus genetic variability and evolution显示文摘Hepatitis C virus(HCV) has infected over 170 million people worldwide and creates a huge disease burden due to chronic, progressive liver disease. HCV is a singlestranded, positive sense, RNA virus, member of the Flaviviridae family. The high error rate of RNA-dependent RNA polymerase and the pressure exerted by the host immune system, has driven the evolution of HCV into 7 different genotypes and more than 67 subtypes. HCV evolves by means of different mechanisms of genetic variation. On the one hand, its high mutation rates generate the production of a large number of different but closely related viral variants during infection, usually referred to as a quasispecies. The great quasispecies variability of HCV has also therapeutic implications since the continuous generation and selection of resistant or fitter variants within the quasispecies spectrum might allow viruses to escape control by antiviral drugs. On the other hand HCV exploits recombination to ensure its survival. This enormous viral diversity together with some host factors has made it difficult to control viral dispersal. Current treatment options involve pegylated interferon-α and ribavirin as dual therapy or in combination with a direct-acting antiviral drug, depending on the country. Despite all the efforts put into antiviral therapy studies, eradication of the virus or the development of a preventive vaccine has been unsuccessful so far. This review focuses on current available data reported to date on the genetic mechanisms driving the molecular evolution of HCV populations and its relation with the antiviral therapies designed to control HCV infection. | Natalia Echeverría Gonzalo Moratorio Juan Cristina Pilar Moreno | 2015 | World Journal of Hepatology2015，7，6： | 5 |
| 3 | Prevalence of vacA, cagA and babA2 genes in Cuban Helicobacter pylori isolates显示文摘AIM: To investigate the prevalence of vacuolating cytotoxin (vacA), cytotoxin associated gene A (cagA) and blood adhesion binding antigen (babA2) genotypes of Helicobacter pylori (H pylori) isolates from Cuban dyspeptic patients. METHODS: DNA was extracted from H pylori-positive cultures taken from 130 dyspeptic patients. Genotyping was performed by PCR, using specifi c primers for vacA (s1, s2, m1, m2), cagA and babA2 genes. Endoscopic observations and histological examinations were used to determine patient pathologies. RESULTS: vacA alleles s1 , s2 , m1 and m2 were detected in 96 (73.8%), 34 (26.2%), 75 (57.7%) and 52 isolates (40%), respectively, while the cagA gene was detected in 95 isolates (73.2%). One hundred and seven isolates (82.3%) were babA2-positive. A signif icant correlation was observed between vacAs1m1 and cagA and between vacAs1m1 and babA2 genotypes (P < 0.001 and P < 0.05, respectively) and between babA2 genotype and cagA status (P < 0.05); but, no correlation was observed between vacAs1 and babA2 genotypes. Eighty fi ve (65.4%) and 73 (56.2%) strains were type 1 (vacAs1-cagA-positive) and 'triple- positive' (vacAs1-cagA-babA2-positive), respectively, and their presence was significantly associated with duodenal ulcer (P < 0.01 and P < 0.001, respectively). CONCLUSION: The distribution of the main virulence factors in the Cuban strains in this study resembled that of the Western-type strains, and the more virulent H pylori isolates were signifi cantly associated with duodenal ulcer, ulcer disease being the worst pathology observed in the group studied. | Lino E Torres Karelia Melián Arlenis Moreno Jordis Alonso Carlos A Sabatier Mayrín Hernández Ludisleydis Bermúdez Boris L Rodríguez | 2009 | World Journal of Gastroenterology2009，15，2： | 4 |
| 4 | Celiac disease serology in patients with different pretest probabilities: Is biopsy avoidable?显示文摘AIM: To establish the diagnostic performance of sev-eral serological tests, individually and in combination, for diagnosing celiac disease (CD) in patients with different pretest probabilities, and to explore potential se- rological algorithms to reduce the necessity for biopsy. METHODS: We prospectively performed duodenal biopsy and serology in 679 adults who had either high risk (n = 161) or low risk (n = 518) for CD. Blood samples were tested using six assays (enzyme-linked immunosorbent assay) that detected antibodies to tissue transglutaminase (tTG) and deamidated gliadin peptide (DGP). RESULTS: CD prevalence was 39.1% in the high-risk population and 3.3% in the low-risk group. In high-risk patients, all individual assays had a high diagnostic efficacy [area under receiving operator characteristic curves (AU ROC): 0.968 to 0.999]. In contrast, assays had a lower diagnostic efficacy (AU ROC: 0.835 to 0.972) in the low-risk group. Using assay combinations, it would be possible to reach or rule out diagnosis of CD without biopsy in 92% of cases in both pretest populations. We observed that the new DGP/tTG Screen assay resulted in a surplus compared to more conventional assays in any clinical situation. CONCLUSION: The DGP/tTG Screen assay could be considered as the best initial test for CD. Combinations of two tests, including a DGP/tTG Screen, might be able to diagnose CD accurately in different clinical scenarios making biopsy avoidable in a high proportion of subjects. | Emilia Sugai María L Moreno Hui J Hwang Ana Cabanne Adriana Crivelli Fabio Nach-man Horacio Vázquez Sonia Niveloni Julio Argonz Roberto Mazure Graciela La Motta María E Caniggia Edgardo Smecuol Néstor Chopita Juan C Gómez Eduardo Maurińo Julio C Bai | 2010 | World Journal of Gastroenterology2010，16，25： | 4 |
| 5 | 在 esophagogastroduodenoscopy 使用 lidocaine 的实用性与 propofol 表现在镇静下面显示文摘 AIM:To determine whether topical lidocaine benefits esophagogastroduoduenoscopy(EGD) by decreasing propofol dose necessary for sedation or procedurerelated complications.METHODS:The study was designed as a prospective,single centre,double blind,randomised clinical trial and was conducted in 2012 between January and May(NCT01489891).Consecutive patients undergoing EGD were randomly assigned to receive supplemental topical lidocaine(L;50 mg in an excipient solution which was applied as a spray to the oropharynx) or placebo(P;taste excipients solution without active substance,similarly delivered) prior to the standard propofol sedation procedure.The propofol was administered as a bolus intravenous(iv) dose,with patients in the L and P groups receiving initial doses based on the patient’s American Society of Anaesthesiologists(ASA) classification(ASAⅠ-Ⅱ:0.50-0.60 mg/kg;ASA Ⅲ-Ⅳ:0.25-0.35 mg/kg),followed by 10-20 mg iv dose every 30-60 s at the anaesthetist’s discretion.Vital signs,anthropometric measurements,amount of propofol administered,sedation level reached,examination time,and the subjective assessments of the endoscopist’s and anaesthetist’s satisfaction(based upon a four point Likert scale) were recorded.All statistical tests were performed by the Stata statistical software suite(Release 11,2009;StataCorp,LP,College Station,TX,United States).RESULTS:No significant differences were found between the groups treated with lidocaine or placebo in terms of total propofol dose(310.7 ± 139.2 mg/kg per minute vs 280.1 ± 87.7 mg/kg per minute,P = 0.15) or intraprocedural propofol dose(135.3 ± 151.7 mg/kg per minute vs 122.7 ± 96.5 mg/kg per minute,P = 0.58).Only when the L and P groups were analysed with the particular subgroups of female,< 65-year-old,and lower anaesthetic risk level(ASA Ⅰ-Ⅱ) was a statistically significant difference found(L:336.5 ± 141.2 mg/kg per minute vs P:284.6 ± 91.2 mg/kg per minute,P = 0.03) for greater total propofol requirements).The total incidence of complications was also similar between the two groups,with the L group showing a complication rate of 32.2%(95%CI:21.6-45.0) and the P group showing a complication rate of 26.7%(95%CI:17.0-39.0).In addition,the use of lidocaine had no effect on the anaesthetist’s or endoscopist’s satisfaction with the procedure.Thus,the endoscopist’s satisfaction Likert assessments were equally distributed among the L and P groups:unsatisfactory,[L:6.8%(95%CI:2.2-15.5) vs P:0%(95%CI:0-4.8);neutral,L:10.1%(95%CI:4.2-19.9) vs P:15%(95%CI:7.6-25.7)];satisfactory,[L:25.4%(95%CI:10-29.6) vs P:18.3%(95%CI:15.5-37.6);and very satisfactory,L:57.6%(95%CI:54-77.7) vs P:66.6%(95%CI:44.8-69.7)].Likewise,the anaesthetist’s satisfaction Likert assessments regarding the ease of maintaining a patient at an optimum sedation level without agitation or modification of the projected sedation protocol were not affected by the application of lidocaine,as evidenced by the lack of significant differences between the scores for the placebo group:unsatisfactory,L:5.8%(95%CI:1.3-13.2) vs P:0%(95%CI:0-4.8);neutral,L:16.9%(95%CI:8.9-28.4) vs P:16.7%(95%CI:8.8-27.7);satisfactory,L:15.2%(95%CI:7.7-26.1) vs P:20.3%(95%CI:11.3-31.6);and very satisfactory,L:62.7%(95%CI:49.9-74.3) vs P:63.3%(95%CI:50.6-74.7).CONCLUSION:Topical pharyngeal anaesthesia is safe in EGD but does not reduce the necessary dose of propofol or improve the anaesthetist’s or endoscopist’s satisfaction with the procedure. | Felipe de la Morena Cecilio Santander Carlos Esteban Beatriz de Cuenca Juan Antonio García Javier Sánchez Ricardo Moreno | 2013 | World Journal of Gastrointestinal Endoscopy2013，5，5： | 3 |
| 6 | On the uncertainty of interwell connectivity estimations from the capacitance-resistance model显示文摘The capacitance-resistance model(CRM) is an alternative to conventional reservoir simulation. CRM, a simplification of complex numerical models, uses production and injection rates to infer a reservoir description. There is no prior geologic model. The principal output of CRM fitting is the fraction of injected fluid(usually water) that is produced at a producer at steady-state. These fractions are interwell connectivities. Interwell connectivities are fundamental information needed to manage waterfloods in oil reservoirs. The data-driven CRM is a fast tool to estimate these parameters in mature fields and allows one to make full use of the dynamic data available. This paper considers the problem of setting an upper bound on the uncertainty of interwell connectivities for linear-constrained models. Using analytical bounds and numerical simulations, we derive a consistent upper limit on the uncertainty of interwell connections that can be used to quantify the information content of a given dataset. | Gustavo A Moreno Larry W Lake | 2014 | Petroleum Science2014，11，2： | 3 |
| 7 | Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis显示文摘 | Marlene Dominguez Rosa Miquel Jordi Colmenero Montserrat Moreno Joan–Carles García–Pagán Jaime Bosch Vicente Arroyo Pere Ginès Juan Caballería Ramón Bataller | 2009 | Gastroenterology2009，，5： | 3 |
| 8 | Use of agents stimulating erythropoiesis in digestive diseases显示文摘Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron def iciency in IBD. There is also a variable component of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin (rHuEPO), which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as f irst choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit (11-12 g/dL). New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same eff icacy and safety. | Rosario Moreno López Beatriz Sicilia Aladrén Fernando Gomollón García | 2009 | World Journal of Gastroenterology2009，15，37： | 2 |
| 9 | Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports显示文摘BACKGROUND In metastatic colorectal cancer(mCRC),the anti-vascular endothelial growth factor drug bevacizumab(BVZ)plus chemotherapy significantly improves progression-free survival compared to chemotherapy(CT)alone.This benefit is not,however,observed in all patients.While increased chemokine CXCL5 gene expression promoting angiogenesis has been proposed as a prognostic mCRC biomarker,few studies have examined its relationship with drug efficacy.This study sought to analyze tumor CXCL5 gene expression in six patients with different efficacy of BVZ-containing CT in terms of the tumor response to treatment.CASE SUMMARY We report six cases of stage IV KRAS-mutated mCRC.Patients were given first line treatment with BVZ-containing chemotherapy in University Hospital of Fuenlabrada.The six patients differed in terms of primary tumor location(right/left side),tumor burden(mostly hepatic and peritoneal disease)and clinical disease course.Before treatment onset,total RNA was isolated from paraffinated tumor biopsy specimens and CXCL5 gene expression quantified through conventional RT-qPCR procedures.Our main finding was that CXCL5 expression levels were several times higher in three patients with lower progression free survival(under 6 mo)from the start of treatment.CONCLUSION A higher expression of CXCL5 was observed in the three patients showing worse tumor response to treatment. | Apolonia Novillo María Gaibar Alicia Romero-Lorca María Fuencisla Gilsanz Laura Beltrán Miguel Galán Beatriz Antón Diego Malón Amalia Moreno Ana Fernández-Santander | 2020 | World Journal of Gastroenterology2020，26，16： | 2 |
| 10 | In vitro antifungal activity of extracts of Mexican Chihuahuan Desert plants against postharvest fruit fungi显示文摘 | D. Jasso de Rodríguez R. Rodríguez García F.D. Hernández Castillo C.N. Aguilar González A. Sáenz Galindo J.A. Villarreal Quintanilla L.E. Moreno Zuccolotto | 2011 | Industrial Crops & Products2011，，1： | 2 |
| 11 | Source origin of trace elements in PM from regional background, urban and industrial sites of Spain显示文摘 | X. Querol M. Viana A. Alastuey F. Amato T. Moreno S. Castillo J. Pey J. de la Rosa A. Sánchez de la Campa B. Artí?ano P. Salvador S. García Dos Santos R. Fernández-Patier S. Moreno-Grau L. Negral M.C. Minguillón E. Monfort J.I. Gil A. Inza L.A. Ortega J.M | 2007 | Atmospheric Environment2007，，34： | 2 |
| 12 | Influence of antiviral therapy in the long‐term outcome of recurrent hepatitis C virus infection following liver transplantation显示文摘 | A. García‐Reyne C. Lumbreras I. Fernández F. Colina M. Abradelo P. Magan R. San‐Juan A. Manrique F. López‐Medrano A. Fuertes M. Lizasoain E. Moreno J.M. Aguado | 2013 | Transpl Infect Dis2013，，4： | 2 |
| 13 | Alcohol dehydrogenase from human stomach: variability in normal mucosa and effect of age, gender, ADH3 phenotype and gastric region显示文摘 | Moreno A Parés A Ortiz J Enriquez J Parés X | 1994 | Alcohol Alcohol1994，29，6： | 2 |
| 14 | Avian Escherichia coli virulence factors associated with coli septicemia in broiler chickens显示文摘 | Ramirez Santoyo R M Moreno Sala A Almanza Marquez Y | 2001 | Rev Argent Mecrobiol2001，33，1： | 2 |
| 15 | GOECP/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma显示文摘Malignant pleural mesothelioma(MPM)is a rare tumor with poor prognosis and rising incidence.Palliative care is common in MPM as radical treatment with curative intent is often not possible due to metastasis or extensive locoregional involvement.Numerous therapeutic advances have been made in recent years,including the use of less aggressive surgical techniques associated with lower morbidity and mortality(e.g.,pleurectomy/decortication),technological advancements in the field of radiotherapy(intensity-modulated radiotherapy,image-guided radiotherapy,stereotactic body radiotherapy,proton therapy),and developments in systemic therapies(chemotherapy and immunotherapy).These improvements have had as yet only a modest effect on local control and survival.Advances in the management of MPM and standardization of care are hampered by the evidence to date,limited by high heterogeneity among studies and small sample sizes.In this clinical guideline prepared by the oncological group for the study of lung cancer of the Spanish Society of Radiation Oncology,we review clinical,histologic,and therapeutic aspects of MPM,with a particular focus on all aspects relating to radiotherapy,including the current evidence base,associations with chemotherapy and surgery,treatment volumes and planning,technological advances,and reradiation. | Javier Luna Andrea Bobo Joaquín José Cabrera-Rodriguez María Pagola Margarita Martín-Martín María Ángeles González Ruiz Miguel Montijano Aurora Rodríguez Lira Pelari-Mici Almudena Corbacho Marta Moreno Felipe Couñago | 2021 | World Journal of Clinical Oncology2021，12，8： | 2 |
| 16 | E6 molecular variants of human papillomavirus (HPV) type 16: An updated and unified criterion for clustering and nomenclature显示文摘 | Antonio Huertas-Salgado Diana C. Martín-Gámez Pablo Moreno Raúl Murillo María Mercedes Bravo Luisa Villa Mónica Molano | 2010 | Virology2010，，： | 2 |
| 17 | Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening显示文摘 | Adolfo Parra-Blanco Antonio Z. Gimeno-García Enrique Quintero David Nicolás Santiago G. Moreno Alejandro Jiménez Manuel Hernández-Guerra Marta Carrillo-Palau Yoshinobu Eishi Julio López-Bastida | 2010 | Journal of Gastroenterology2010，，7： | 2 |
| 18 | 在经历 transcatheter 的病人的 atrial 纤维性颤动的临床、预示的含意大动脉的阀门培植显示文摘 AIM: To study a cohort of consecutive patients under-going transcatheter aortic valve implantation (TAVI) and compare the outcomes of atrial fibrillation (AF) patients vs patients in sinus rhythm (SR). METHODS: All consecutive patients undergoing TAVI in our hospital were included. The AF group comprised patients in AF at the time of TAVI or with history of AF, and were compared with the SR group. Procedural, echocardiographic and follow-up variables were compared. Likewise, the CHA 2 DS 2-VASC stroke risk score and HAS-BLED bleeding risk score and antithrombotic treatment at discharge in AF patients were compared with that in SR patients. RESULTS: From a total of 34 patients undergoing TAVI, 17 (50%) were allocated to the AF group, of whom 15 (88%) were under chronic oral anticoagulation. Patients in the AF group were similar to those in the SR group except for a trend (P = 0.07) for a higher logistic EuroSCORE (28% vs 19%), and a higher prevalence of hypertension (82% vs 53%) and chronic renal failure (17% vs 0%). Risk of both stroke and bleeding was high in the AF group (mean CHA 2 DS 2-VASC 4.3, mean HAS-BLED 2.9). In the AF group, treatment at discharge included chronic oral anticoagulation in all except one case, and in association with an antiplatelet drug in 57% of patients. During a mean follow-up of 11 mo (maximum 32), there were only two strokes, none of them during the peri-procedural period: one in the AF group at 30 mo and one in the SR group at 3 mo. There were no statistical differences in procedural success, and clinical outcome (survival at 1 year 81% vs 74% in AF and SR groups, respectively, P = NS). CONCLUSION: Patients in AF undergoing TAVI show a trend to a higher surgical risk. However, in our cohort, patients in AF did not have a higher stroke rate compared to the SR group, and the prognosis was similar in both groups. | Pablo Salinas Raúl Moreno Luis Calvo Santiago Jiménez-Valero Guillermo Galeote Angel Sánchez-Recalde Teresa López-Fernández Sergio Garcia-Blas Diego Iglesias Luis Riera Isidro Moreno-Gómez Jose María Mesa Ignacio Plaza Rocio Ayala Rosa Gonzalez José-Luis López-Sendón | 2012 | World Journal of Cardiology2012，4，1： | 2 |
| 19 | Expression profiles of Dax1,Dmrt1,and Sox9 during temperature sex determination in gonads of the sea turtle Lepidochelys olivacea显示文摘 | Landa P A Moreno M N | 2002 | Genaral & Comparative Endocrinology2002，129，1： | 1 |
| 20 | Microwaves in organic synthesis,thermal and non-thermal microwave effects显示文摘 | De la Hoz A Diaz-Ortiz A Moreno A | 2005 | Chemical Society Review2005，34，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员